Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer

International Journal of Hematology

Volumn 90, Issue 5, 2009, Pages 627-634

  Cheng, Yee Chung ^a,b   Rondón, Gabriela ^a   Sanchez, Leah F ^a   McMannis, John D ^a   Couriel, Daniel R ^a   De Lima, Marcos J ^a   Hosing, Chitra ^a   Khouri, Issa F ^a   Giralt, Sergio A ^a   Champlin, Richard E ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Autologous hematopoietic stem cell transplantation; Granulocyte macrophage colony stimulating factor; High dose chemotherapy; Interleukin 2; Metastatic breast cancer

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE METASTASIS; BONE PAIN; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CELL ACTIVATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; EX VIVO STUDY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HYPOTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER METASTASIS; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OVARY METASTASIS; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PLEURA METASTASIS; PROGRESSION FREE SURVIVAL; REPEATED DRUG DOSE; STEM CELL MOBILIZATION; SURVIVAL RATE; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMODULATION; INTERLEUKIN-2; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73449120674     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0439-6     Document Type: Article

References (44)

1. PA Greenberg GN Hortobagyi TL Smith LD Ziegler DK Frye AU Buzdar 1996 Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 2197 2205 8708708
2. JP Eder K Antman W Peters WD Henner A Elias T Shea, et al. 1986 High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer J Clin Oncol 4 1592 1597 3534155 (Pubitemid 17188925)
3. WP Peters EJ Shpall RB Jones GA Olsen RC Bast JP Gockerman, et al. 1988 High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 6 1368 1376 3047332
4. SF Williams R Mick R Desser J Golick J Beschorner JD Bitran 1989 High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer J Clin Oncol 7 1824 1830 2511276
5. MJ Kennedy RA Beveridge SD Rowley GB Gordon MD Abeloff NE Davidson 1991 High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer J Natl Cancer Inst 83 920 926 10.1093/jnci/83.13.920 1906111
6. SF Williams T Gilewski R Mick JD Bitran 1992 High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report J Clin Oncol 10 1743 1747 1357109
7. K Antman L Ayash A Elias C Wheeler M Hunt JP Eder, et al. 1992 A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy J Clin Oncol 10 102 110 1727912
8. KH Antman PA Rowlings WP Vaughan CJ Pelz JW Fay KK Fields, et al. 1997 High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America J Clin Oncol 15 1870 1879 9164197
9. CH Weaver WH West LS Schwartzberg T Alberico R Leff FA Greco, et al. 1997 Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses Bone Marrow Transplant 19 661 670 10.1038/sj.bmt.1700728 9156242
10. WI Bensinger KS Schiffman L Holmberg FR Appelbaum R Maziarz P Montgomery, et al. 1997 High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer Bone Marrow Transplant 19 1183 1189 10.1038/sj.bmt.1700820 9208111
11. P Ljungman B Bjorkstrand T Fornander M Hoglund G Juliusson H Lindman, et al. 1998 High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer Bone Marrow Transplant 22 445 448 10.1038/sj.bmt.1701367 9733267
12. M Crump S Gluck D Tu D Stewart M Levine P Kirkbride, et al. 2008 Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem cell support compared with standard-dose chemotherapy in women with metastatic breast cancer. NCIC MA.16 J Clin Oncol 26 37 43 10.1200/JCO.2007.11.8851 18025439
13. H Roche P Viens P Biron JP Lotz B Asselain 2003 High-dose chemotherapy for breast cancer: the French PEGASE experience Cancer Control 10 42 47 12598854
14. P Biron M Durand H Roche T Delozier C Battista P Fargeot, et al. 2008 Pegase 3: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer Bone Marrow Transplant 41 555 562 10.1038/sj.bmt.1705935 18037940
15. JP Lotz H Cure M Janvier B Asselain F Morvan M Legros, et al. 2005 High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol Eur J Cancer 41 71 80 10.1016/j.ejca.2004.09. 006 15617992 (Pubitemid 40036610)
16. Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, et al. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant. 2006;12:195-203.
17. Vredenburgh JJ, Madan B, Coniglio D, Ross M, Broadwater G, Niedzwiecki D, et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant. 2006;37:1009-15.
18. EA Stadtmauer A O'Neill LJ Goldstein PA Crilley KF Mangan JN Ingle, et al. 2000 Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group N Engl J Med 342 1069 1076 10.1056/NEJM200004133421501 10760307 (Pubitemid 30207689)
19. NT Ueno G Rondon NQ Mirza DK Geisler P Anderlini SA Giralt, et al. 1998 Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer J Clin Oncol 16 986 993 9508181
20. NT Ueno YC Cheng G Rondon NM Tannir JL Gajewski DR Couriel, et al. 2003 Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors Blood 102 3829 3836 10.1182/blood-2003-04-1022 12881308 (Pubitemid 37409408)
21. MR Bishop DH Fowler D Marchigiani K Castro C Kasten-Sportes SM Steinberg, et al. 2004 Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer J Clin Oncol 22 3886 3892 10.1200/JCO.2004.01.127 15314059 (Pubitemid 41079869)
22. J Lister WB Rybka AD Donnenberg M deMagalhaes-Silverman SM Pincus EJ Bloom, et al. 1995 Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period Clin Cancer Res 1 607 614 9816022
23. KR Meehan A Badros SR Frankel R Cahill E Areman M Jenson, et al. 1997 A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies J Hematother 6 457 464 9368182
24. N Robinson MC Benyunes JA Thompson A York S Petersdorf O Press, et al. 1997 Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study Bone Marrow Transplant 19 435 442 10.1038/sj.bmt.1700687 9052908
25. K Margolin SJ Forman 2000 Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy Cancer J Sci Am 6 Suppl 1 S33 S38 10685656
26. EM Areman A Mazumder PL Kotula UN Verma C Rajagopal S Hancock, et al. 1996 Hematopoietic potential of IL-2-cultured peripheral blood stem cells from breast cancer patients Bone Marrow Transplant 18 521 525 8879612
27. G Gravis P Viens N Vey D Blaise AM Stoppa D Olive, et al. 2000 Pilot study of immunotherapy with interleukin-2 after autologous stem cell transplantation in advanced breast cancers Anticancer Res 20 3987 3991 11268489
28. KR Meehan UN Verma R Cahill S Frankel EM Areman RA Sacher, et al. 1997 Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates Bone Marrow Transplant 20 643 651 10.1038/sj.bmt.1700954 9383227
29. KR Meehan B Arun EA Gehan B Berberian V Sulica EM Areman, et al. 1999 Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer Bone Marrow Transplant 23 667 673 10.1038/sj.bmt.1701632 10218842
30. HC Toh SL McAfee R Sackstein P Multani BF Cox R Garcia-Carbonero, et al. 2000 High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma: a phase II study Bone Marrow Transplant 25 19 24 10.1038/sj.bmt.1702091 10654009
31. LJ Burns DJ Weisdorf TE DeFor TL Repka KM Ogle C Hummer, et al. 2000 Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer Exp Hematol 28 96 103 10.1016/S0301-472X(99)00129-0 10658681 (Pubitemid 30047195)
32. Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, et al. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem cell graft and post-stem cell infusion. J Clin Oncol. 2001;19:634-44.
33. LJ Burns DJ Weisdorf TE DeFor DH Vesole TL Repka BR Blazar, et al. 2003 IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial Bone Marrow Transplant 32 177 186 10.1038/sj.bmt.1704086 12838283 (Pubitemid 36903442)
34. CA Savary ML Grazziutti B Melichar D Przepiorka RS Freedman RE Cowart, et al. 1998 Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients Cancer Immunol Immunother 45 234 240 10.1007/s002620050438 9439646
35. AA Hakim 1988 Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptors Cancer 61 689 701 10.1002/1097-0142(19880215)61: 4<689::AID-CNCR2820610412>3.0.CO;2-O 2962732
36. C Cordon-Cardo Z Fuks M Drobnjak C Moreno L Eisenbach M Feldman 1991 Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas Cancer Res 51 6372 6380 1933900
37. S Yamasaki N Kan K Mise T Harada Y Ichinose Y Moriguchi, et al. 1993 Cellular interaction against autologous tumor cells between IL-2-cultured lymphocytes and fresh peripheral blood lymphocytes in patients with breast cancer given immuno-chemotherapy Biotherapy 6 63 71 10.1007/BF01877387 8507545
38. G Konjevic I Spuzic 1993 Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer Neoplasma 40 81 85 8350959
39. S Arduino M Tessarolo R Bellino S Colombatto L Leo T Wierdis, et al. 1996 Reduced IL-2 level concentration in patients with breast cancer as a possible risk factor for relapse Eur J Gynaecol Oncol 17 535 537 8971538
40. M Chen-Woan CP Delaney V Fournier Y Wakizaka N Murase J Fung, et al. 1995 A new protocol for the propagation of dendritic cells from rat bone marrow using recombinant GM-CSF, and their quantification using the mAb OX-62 J Immunol Methods 178 157 171 10.1016/0022-1759(94)00253-S 7836778
41. P Szabolcs ED Feller MA Moore JW Young 1995 Progenitor recruitment and in vitro expansion of immunostimulatory dendritic cells from human CD34+ bone marrow cells by c-kit-ligand, GM-CSF, and TNF alpha Adv Exp Med Biol 378 17 20 8526047
42. C Caux B Vanbervliet C Massacrier C Dezutter-Dambuyant B de Saint-Vis C Jacquet, et al. 1996 CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF alpha J Exp Med 184 695 706 10.1084/jem.184.2.695 8760823
43. F Montemurro G Rondon M Munsell TL Smith ML Donato JL Gajewski, et al. 2003 Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection Biol Blood Marrow Transplant 9 330 340 10.1016/S1083-8791(03)00088-0 12766883 (Pubitemid 38351818)
44. UA Nitz S Mohrmann J Fischer W Lindemann WE Berdel C Jackisch, et al. 2005 Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial Lancet 366 1935 1944 10.1016/S0140-6736(05)67784-7 16325695 (Pubitemid 41713983)